Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

And regular polling carried out by YouGov suggests adults are increasingly likely to say that vaccines have harmful side effects that are not being disclosed to the public. The proportion saying that ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...